Passionate about promoting inclusivity of diverse leadership styles, our CEO and Founder, Dr Danuta Jeziorska (she/her), highlights how we can help empower female leaders in business.

Happy International Women’s Day! #iwd2024

Our CEO & Founder, Dr Danuta Jeziorska (she/her), is featured in the latest instalment of Scrip, Citeline Commercial #ScripAsks series by Eleanor Malone on the transformative technologies poised to shape 2024.

👉 You can read the article here: lnkd.in/dWeM2Bcy
 
#2024Predictions #DarkGenome #Genomics

Join us to decode the genetics located in the #darkgenome to discover & develop #precisionmedicine .

We're currently recruiting for 3 pivotal roles: 2 Snr Scientists & Scientist in #FunctionalGenomics .
To apply: nucleome.com/careers/

#Genomics #GeneRegulation #3Dgenome #Oxford

Our CEO & Co-founder Dr Danuta Jeziorska (she/her),
Co-Founder Jim Hughes,
CBO Nigel Clark, &
CSO Steve Harrison, will be attending the JP Morgan Healthcare Conference in San Francisco, 08-11 January 2024.
 
We are looking forward to meeting with potential partners & collaborators.

  #JPM2024

As we closed 2023, our CEO & Founder Danuta Jeziorska reflected on the milestones the Company has achieved:

linkedin.com/posts/nucleome…

We’ve been spotlighted in two recent industry features! 
 
UKT News’ Which UK Genetics Startups are Revolutionising Biotechnology in 2023? lnkd.in/eWnmcBYX

AlbionVC’s 2023 European HealthTech Market Map in the category of Digital Pharma - Tech Bio
 lnkd.in/e4BAJtf6

🔦 Genetics Unzipped – Afraid of the dark?
Our CEO & Founder Dr Danuta Jeziorska (she/her) is a guest on the latest episode of #genetics Unzipped with Kat Arney, which is now online and ready for you to tune in!
👉 You can listen to the podcast here: geneticsunzipped.com/blog/2023/14/1…

We are excited to share that the appointment of our new Chief Scientific Officer, Stephen Harrison, has been featured in BioCentury
Read the full article here:  biocentury.com/article/650662…
#Appointment #Genomics #DarkGenome #DrugDiscovery #PrecisionMedicine

We are excited to welcome Dr. Stephen Harrison to Nucleome Therapeutics as our Chief Scientific Officer, bringing 30 years of drug discovery and development expertise as the Company continues to build a portfolio of first-in-class targets.
lnkd.in/e5rjdgkH

The #DarkGenome Symposium starts today, and we are delighted that leaders from across academia, biotech, pharma, and investment gathered to discuss the latest advancement in the Dark Genome field and their translation to precision medicine.

Our CEO Dr Danuta Jeziorska (she/her) spoke to Oxford University Innovation about the pioneering work we do at Nucleome Therapeutics and being part of Oxford’s thriving life sciences innovation scene.

Read the full article here: innovation.ox.ac.uk/news/oxford-li…

#Oxford #Biotech #DarkGenome #Genomics

Delighted that Nucleome is showcased as one of the 50 companies in PwC UK’s 'Life Sciences Future 50' report, illustrating the world-class science and innovation being led by the UK’s life sciences sector.

Read the report here: bit.ly/3Fnw379

Nucleome has been shortlisted in the Biotech of the Year category at the European European Lifestars Awards – a testament to our commitment to decoding the dark matter of the human genome to develop first-in-class precision medicines.

Nucleome Therapeutics has been featured in a new BioCentury. Emerging Company Profile by Karen Tkach Tuzman

The article discusses the dark genome, Nucleome’s innovative 3D genome methods, our origins, as well as an interview with our CEO Dr Danuta Jeziorska (she/her)

biocentury.com/article/648954…

Our CEO Dr Danuta Jeziorska (she/her) is interviewed as part of Creative Destruction Lab (CDL) Oxford new article celebrating that startups from the Oxford Creative Destruction Lab programme, based in the Oxford Saïd Insights University of Oxford have collectively created a record £1.3bn in equity value!
lnkd.in/eSHZmnUU

Great to see Dr Russell Greig's appointment as Non-Executive Chair of Nucleome Therapeutics featured in BioCentury.

biocentury.com/article/649192…

#genomics #darkgenome #biotech #appointment

Dr Russell Greig’s appointment as our Chair was featured in Endpoints News.

Read about it here: endpts.com/glyscend-taps-…

#genomics #darkgenome #biotech #appointment

We are delighted to welcome Dr Russell Greig as Non-Executive Chair of our Board of Directors! He brings over four decades of experience in the biopharmaceutical industry, including more than 30 years at GSK.

To read more:  lnkd.in/eSy4pcFq

#genomics #darkgenome